What question did this study set out to answer?

To determine whether the lower incidence of end-stage renal disease in Europe compared to the United States stems from differences in early chronic kidney disease prevalence or varying rates of disease progression.

June 21, 2006Journal of the American Society of Nephrology

International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk

View Full Paper

Ask AI

Bookmark

Population

84,770 adults from population-based surveys in Norway and the United States.

Design

Cohort

Authors

SHStein Hallan JCJosef Coresh BABrad C. Astor

Discussion

Member takes

Overview

Lower progression rates may explain lower European ESRD incidence; hypothesis-generating for modifiable determinants beyond prevalence.

Key Points

To determine whether the lower incidence of end-stage renal disease in Europe compared to the United States stems from differences in early chronic kidney disease prevalence or varying rates of disease progression.
Analyzed cross-sectional health survey data from Norway's HUNT II cohort (n=65,181; 1995–1997) and US NHANES surveys (n=15,488 in 1988–1994; n=4,101 in 1999–2000) using standardized sex-specific persistent albuminuria and glomerular filtration rate cutoffs.
Extracted end-stage renal disease incidence from national registries to estimate the relative risk of progressing from stages 3 and 4 chronic kidney disease to kidney failure.
Total chronic kidney disease prevalence was 10.2% in Norway (stage 1: 2.7%, stage 2: 3.2%, stage 3: 4.2%, stage 4: 0.2%), matching US prevalence rates of 11.0% (1988–1994) and 11.7% (1999–2000).
US white patients had a higher progression risk from chronic kidney disease stages 3 or 4 to end-stage renal disease than Norwegian patients (relative risk 2.5), an association that persisted after adjustment for age, gender, and diabetes.

Structured PICO

Population

84,770 adults from population-based surveys in Norway (HUNT II, n=65,181) and the United States (NHANES 1988-1994, n=15,488; NHANES 1999-2000, n=4,101).

Outcome

Prevalence of chronic kidney disease (CKD) stages and relative risk of progression to end-stage renal disease (ESRD)hard clinical

The lower incidence of ESRD in Europe compared to the US is likely due to a lower rate of progression to ESRD rather than a lower prevalence of earlier-stage CKD.

Cite This Study

Hallan et al. (2006) studied this question.

synapsesocial.com/papers/6a7d0cdf342883c6199ffb94 https://doi.org/10.1681/asn.2005121273

View Full Paper

Ask AI

Bookmark

June 21, 2006Journal of the American Society of Nephrology

International Comparison of the Relationship of Chronic Kidney Disease Prevalence and ESRD Risk

View Full Paper

Ask AI

Bookmark

Population

84,770 adults from population-based surveys in Norway and the United States.

Design

Cohort

Authors

SHStein Hallan JCJosef Coresh BABrad C. Astor

Discussion

Member takes

Overview

Lower progression rates may explain lower European ESRD incidence; hypothesis-generating for modifiable determinants beyond prevalence.

Key Points

To determine whether the lower incidence of end-stage renal disease in Europe compared to the United States stems from differences in early chronic kidney disease prevalence or varying rates of disease progression.
Analyzed cross-sectional health survey data from Norway's HUNT II cohort (n=65,181; 1995–1997) and US NHANES surveys (n=15,488 in 1988–1994; n=4,101 in 1999–2000) using standardized sex-specific persistent albuminuria and glomerular filtration rate cutoffs.
Extracted end-stage renal disease incidence from national registries to estimate the relative risk of progressing from stages 3 and 4 chronic kidney disease to kidney failure.
Total chronic kidney disease prevalence was 10.2% in Norway (stage 1: 2.7%, stage 2: 3.2%, stage 3: 4.2%, stage 4: 0.2%), matching US prevalence rates of 11.0% (1988–1994) and 11.7% (1999–2000).
US white patients had a higher progression risk from chronic kidney disease stages 3 or 4 to end-stage renal disease than Norwegian patients (relative risk 2.5), an association that persisted after adjustment for age, gender, and diabetes.

Structured PICO

Population

84,770 adults from population-based surveys in Norway (HUNT II, n=65,181) and the United States (NHANES 1988-1994, n=15,488; NHANES 1999-2000, n=4,101).

Outcome

Prevalence of chronic kidney disease (CKD) stages and relative risk of progression to end-stage renal disease (ESRD)hard clinical

The lower incidence of ESRD in Europe compared to the US is likely due to a lower rate of progression to ESRD rather than a lower prevalence of earlier-stage CKD.

Cite This Study

Hallan et al. (2006) studied this question.

synapsesocial.com/papers/6a7d0cdf342883c6199ffb94 https://doi.org/10.1681/asn.2005121273

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark